{"id":"NCT01144364","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)","officialTitle":"A Randomized, Open-label Study of MabThera Maintenance Therapy Compared With no Further Therapy After a Brief Induction With Chemotherapy Plus MabThera on Failure-free Survival in Treatment-na√Øve Elderly Patients With Advanced Follicular Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-01-19","primaryCompletion":"2011-07-21","completion":"2011-07-21","firstPosted":"2010-06-15","resultsPosted":"2014-12-04","lastUpdate":"2017-08-15"},"enrollment":234,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Hodgkin's Lymphoma"],"interventions":[{"type":"DRUG","name":"rituximab [Mabthera/Rituxan]","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy and safety of brief induction therapy with a chemotherapeutic regimen containing MabThera, followed by either maintenance therapy with MabThera or no further therapy. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.","primaryOutcome":{"measure":"Percentage of Participants With Disease Progression or Death","timeFrame":"12, 24, and 34 months","effectByArm":[{"arm":"Rituximab Induction, Rituximab Maintenance","deltaMin":29.7,"sd":null},{"arm":"Rituximab Induction, Observation Maintenance","deltaMin":34.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.254"}]},"eligibility":{"minAge":"60 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":45,"countries":["Italy"]},"refs":{"pmids":["24085766","23960180"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":233},"commonTop":["Neutropenia","Thrombocytopenia","Anaemia","Asthenia/fatigue","Pyrexia"]}}